CA2919572C - Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them - Google Patents
Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- CA2919572C CA2919572C CA2919572A CA2919572A CA2919572C CA 2919572 C CA2919572 C CA 2919572C CA 2919572 A CA2919572 A CA 2919572A CA 2919572 A CA2919572 A CA 2919572A CA 2919572 C CA2919572 C CA 2919572C
- Authority
- CA
- Canada
- Prior art keywords
- tetrahydroisoquinoline
- group
- methyl
- branched
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR13/57276 | 2013-07-23 | ||
| FR1357276A FR3008977A1 (fr) | 2013-07-23 | 2013-07-23 | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| PCT/EP2014/065764 WO2015011164A1 (en) | 2013-07-23 | 2014-07-22 | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2919572A1 CA2919572A1 (en) | 2015-01-29 |
| CA2919572C true CA2919572C (en) | 2017-06-20 |
Family
ID=49911606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2919572A Active CA2919572C (en) | 2013-07-23 | 2014-07-22 | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
Country Status (49)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008977A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| BR112018071548A2 (pt) | 2016-04-20 | 2019-04-16 | Bristol-Myers Squibb Company | compostos heterocíclicos bicíclicos substituídos |
| BR112020026580A2 (pt) | 2018-06-27 | 2021-03-23 | Proteostasis Therapeutics, Inc. (Fem) | Compostos, composição farmacêutica e métodos para tratar um paciente |
| KR20220102622A (ko) * | 2019-11-15 | 2022-07-20 | 우한 엘엘 사이언스 앤드 테크놀로지 디벨롭먼트 컴퍼니, 리미티드 | Rock 억제제 및 이의 제조 방법과 용도 |
| CN112010796B (zh) * | 2020-09-17 | 2022-04-22 | 浙江大学 | 光学活性3-(1,1-二氟-2-氧-2-芳基乙基)异吲哚啉-1-酮衍生物制备方法 |
| JP2024511277A (ja) | 2021-02-19 | 2024-03-13 | メビオン・メディカル・システムズ・インコーポレーテッド | 粒子線治療システムのためのガントリー |
| CN116997544A (zh) * | 2021-03-24 | 2023-11-03 | 法国施维雅药厂 | 用于合成5-{5-氯-2-[(3s)-3-[(吗啉-4-基)甲基]-3,4-二氢异喹啉-2(1h)-羰基]苯基}-1,2-二甲基-1h-吡咯-3-甲酸衍生物的新方法及其在生产药物化合物中的应用 |
| US20250179047A1 (en) | 2022-02-24 | 2025-06-05 | Les Laboratoires Servier | 5-[7-(3,4-dihydro-1h-isoquinoline-2-carbonyl)-1,2,3,4 tetrahydroisoquinolin-6-yl]-1h-pyrrole-3-carboxamide derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents |
| CN120787162A (zh) | 2022-05-20 | 2025-10-14 | 诺华股份有限公司 | 抗肿瘤化合物的抗体-药物缀合物及其使用方法 |
| WO2024204846A1 (ja) * | 2023-03-31 | 2024-10-03 | 三井化学株式会社 | カルバメート化合物 |
| PY24103486A (es) | 2023-11-22 | 2025-06-06 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| TW202540186A (zh) | 2023-11-22 | 2025-10-16 | 瑞士商諾華公司 | 抗ｃｄ７抗體藥物結合物及其使用方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1501514B1 (en) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| WO2004096774A1 (en) * | 2003-05-01 | 2004-11-11 | Glaxo Group Limited | Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents |
| US20050070570A1 (en) | 2003-06-18 | 2005-03-31 | 4Sc Ag | Novel potassium channels modulators |
| CA2577752A1 (en) * | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| EP1778206A4 (en) * | 2004-08-20 | 2009-08-05 | Univ Michigan | SMALL MOLECULE INHIBITORS FROM MEMBERS OF THE ANTIOPTOTIC BCL-2 FAMILY AND USES THEREOF |
| WO2006087309A1 (en) * | 2005-02-15 | 2006-08-24 | Novo Nordisk A/S | 3,4-dihydro-1h-isoquinoline-2-carboxylic acid 5-aminopyridin-2-yl esters |
| KR101511074B1 (ko) | 2007-04-16 | 2015-04-13 | 애브비 인코포레이티드 | 7-치환된 인돌 Ｍｃｌ-1 억제제 |
| AU2008334075A1 (en) | 2007-11-30 | 2009-06-11 | Biota Scientific Management Pty Ltd | Tetrahydro-isoquinoline PPAT inhibitors as antibacterial agents |
| JP5496915B2 (ja) | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ，インコーポレーテッド | ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法 |
| WO2009102463A2 (en) | 2008-02-14 | 2009-08-20 | Connor Reynolds | Pet waste vacuum system and apparatus, disposable liners therefor, and a method of collecting pet waste using same |
| CN103732589B (zh) * | 2011-05-25 | 2016-03-30 | 百时美施贵宝公司 | 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺 |
| JP2015503518A (ja) * | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Ｂｃｌ２と結合相手の相互作用を阻害するための化合物 |
| WO2013100890A1 (en) | 2011-12-27 | 2013-07-04 | Intel Corporation | Methods and systems to control power gates during an active state of a gated domain based on load conditions of the gated domain |
| FR2986002B1 (fr) * | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008977A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008979B1 (fr) * | 2013-07-23 | 2015-07-24 | Servier Lab | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2013
- 2013-07-23 FR FR1357276A patent/FR3008977A1/fr not_active Withdrawn
-
2014
- 2014-07-13 JO JOP/2014/0223A patent/JO3457B1/ar active
- 2014-07-15 UY UY0001035664A patent/UY35664A/es active IP Right Grant
- 2014-07-22 JP JP2016528512A patent/JP6395829B2/ja active Active
- 2014-07-22 EP EP14741648.1A patent/EP3024826B1/en active Active
- 2014-07-22 HU HUE14741648A patent/HUE041443T2/hu unknown
- 2014-07-22 WO PCT/EP2014/065764 patent/WO2015011164A1/en not_active Ceased
- 2014-07-22 CN CN201480042422.3A patent/CN105431422B/zh active Active
- 2014-07-22 ES ES14741648T patent/ES2711371T3/es active Active
- 2014-07-22 MY MYPI2016700106A patent/MY193619A/en unknown
- 2014-07-22 SG SG11201600205XA patent/SG11201600205XA/en unknown
- 2014-07-22 NZ NZ716155A patent/NZ716155A/en unknown
- 2014-07-22 UA UAA201601395A patent/UA117490C2/uk unknown
- 2014-07-22 TW TW103125161A patent/TWI560184B/zh not_active IP Right Cessation
- 2014-07-22 RS RS20190150A patent/RS58344B1/sr unknown
- 2014-07-22 PE PE2016000023A patent/PE20160241A1/es unknown
- 2014-07-22 PL PL14741648T patent/PL3024826T3/pl unknown
- 2014-07-22 MA MA38801A patent/MA38801B1/fr unknown
- 2014-07-22 SI SI201431038T patent/SI3024826T1/sl unknown
- 2014-07-22 AR ARP140102713A patent/AR097009A1/es active IP Right Grant
- 2014-07-22 GE GEAP201414063A patent/GEP20207070B/en unknown
- 2014-07-22 DK DK14741648.1T patent/DK3024826T3/en active
- 2014-07-22 BR BR112016001080-9A patent/BR112016001080B1/pt active IP Right Grant
- 2014-07-22 AP AP2016008989A patent/AP2016008989A0/xx unknown
- 2014-07-22 KR KR1020167004570A patent/KR102008431B1/ko active Active
- 2014-07-22 ME MEP-2019-35A patent/ME03346B/me unknown
- 2014-07-22 EA EA201600122A patent/EA032301B1/ru unknown
- 2014-07-22 MD MDA20160018A patent/MD4793C1/ro not_active IP Right Cessation
- 2014-07-22 AU AU2014295101A patent/AU2014295101B2/en active Active
- 2014-07-22 CN CN201811358313.9A patent/CN109456324B/zh active Active
- 2014-07-22 PT PT14741648T patent/PT3024826T/pt unknown
- 2014-07-22 HK HK16106761.6A patent/HK1218754A1/zh unknown
- 2014-07-22 HR HRP20190277TT patent/HRP20190277T1/hr unknown
- 2014-07-22 CU CUP2016000010A patent/CU24352B1/xx unknown
- 2014-07-22 TN TN2016000003A patent/TN2016000003A1/en unknown
- 2014-07-22 RU RU2016106003A patent/RU2689305C2/ru active
- 2014-07-22 TR TR2018/19155T patent/TR201819155T4/tr unknown
- 2014-07-22 GE GEAP201914063A patent/GEAP201914063A/en unknown
- 2014-07-22 CA CA2919572A patent/CA2919572C/en active Active
- 2014-07-22 LT LTEP14741648.1T patent/LT3024826T/lt unknown
- 2014-07-22 MX MX2016000904A patent/MX365373B/es active IP Right Grant
- 2014-07-22 US US14/905,985 patent/US9809574B2/en active Active
-
2016
- 2016-01-03 IL IL243449A patent/IL243449A0/en active IP Right Grant
- 2016-01-06 PH PH12016500034A patent/PH12016500034A1/en unknown
- 2016-01-11 ZA ZA2016/00198A patent/ZA201600198B/en unknown
- 2016-01-11 DO DO2016000009A patent/DOP2016000009A/es unknown
- 2016-01-15 CR CR20160030A patent/CR20160030A/es unknown
- 2016-01-20 CL CL2016000148A patent/CL2016000148A1/es unknown
- 2016-01-21 SA SA516370439A patent/SA516370439B1/ar unknown
- 2016-01-21 NI NI201600016A patent/NI201600016A/es unknown
-
2017
- 2017-09-14 US US15/704,330 patent/US10689364B2/en active Active
-
2019
- 2019-02-11 CY CY20191100175T patent/CY1121247T1/el unknown
-
2020
- 2020-05-04 US US16/865,799 patent/US11028070B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2919572C (en) | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | |
| CN104341451B (zh) | 新磷酸酯化合物、其制备方法及含有它们的药物组合物 | |
| US10258626B2 (en) | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them | |
| CA3182507A1 (en) | Inhibitors of kras g12c protein and uses thereof | |
| CN104854101B (zh) | Alk激酶抑制剂 | |
| TW202204364A (zh) | Rip1k抑制劑 | |
| WO2014078372A1 (en) | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors | |
| KR20170063590A (ko) | 신규한 화합물 | |
| JP2018530527A (ja) | Ｅｚｈ２の阻害剤 | |
| CA3086370A1 (en) | Tricyclic inhibitors of the bcl6 btb domain protein-protein interaction and uses thereof | |
| KR20200083529A (ko) | 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물 | |
| EP4267587A2 (en) | Inhibitors of peptidylarginine deiminases | |
| MX2011000329A (es) | Derivados anticancerosos de 4-oxo-l, 4-dihidro-quinolina su preparacion y su uso terapeutico. | |
| WO2024149239A1 (zh) | 杂芳环化合物及其制备方法和用途 | |
| WO2024199444A1 (zh) | 杂芳环化合物及其制备方法和用途 | |
| OA17896A (en) | New compounds Isoindoline or Isoquinoline, process for their preparation and pharmaceutical compositions containing them. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160112 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250603 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250603 |